217 related articles for article (PubMed ID: 10824460)
1. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H
Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
Kasaoka Y; Nakamoto T; Wang J; Usui T; Hamada H
Hiroshima J Med Sci; 2000 Mar; 49(1):29-35. PubMed ID: 10824454
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
Hara I; Nagai H; Miyake H; Yamanaka K; Hara S; Micallef MJ; Kurimoto M; Gohji K; Arakawa S; Ichihashi M; Kamidono S
Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360
[TBL] [Abstract][Full Text] [Related]
6. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
7. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
8. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y
Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545
[TBL] [Abstract][Full Text] [Related]
9. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
11. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T
Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
[TBL] [Abstract][Full Text] [Related]
12. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene.
Tao G; Hu J; Zou H; Lin Q; Liu F; Wu Y; Sun Q
Chin Med J (Engl); 2001 Jun; 114(6):623-7. PubMed ID: 11780440
[TBL] [Abstract][Full Text] [Related]
14. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
[TBL] [Abstract][Full Text] [Related]
15. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
16. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
17. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells.
Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K
Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033
[TBL] [Abstract][Full Text] [Related]
18. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity.
Si SY; Hu PZ; Huang YY; Ye J; Huang Y; Li ZS; Ge W; Li X; Qu P; Zhang XM; Sui YF
Biochem Biophys Res Commun; 2006 Aug; 347(1):208-14. PubMed ID: 16814254
[TBL] [Abstract][Full Text] [Related]
19. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
20. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma.
Younes E; Haas GP; Dezso B; Ali E; Maughan RL; Kukuruga MA; Montecillo E; Pontes JE; Hillman GG
Cell Immunol; 1995 Oct; 165(2):243-51. PubMed ID: 7553889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
